Viral Antigen Ingredients TRIZ Cases

Intratumoral influenza vaccination turns cold tumors hot, boosting immune cell infiltration and checkpoint blockade response.

Promiscuous 18-55 amino acid polypeptides broaden HLA-DR presentation while preserving antigen-specific T-cell activation in cancer vaccines.

Man9-V3 glycopeptide immunogens mimic native Env V3-glycan epitopes to induce broadly neutralizing HIV-1 antibodies.

A heterodimeric anti-STEAP1 antibody redirects T-cell cytotoxicity to prostate tumor cells while limiting off-target effects.

TOPO cloning, LR recombination, and AD293 packaging enable a recombinant adenovirus expressing ASFV EP153R-EP402R for vaccine development.

RNA-LPX encoding HPV E6/E7 drives durable T cell responses to shrink HPV-positive tumors, improve survival, and reduce treatment morbidity.

New attenuated avian reovirus strains match circulating isolates to safely protect poultry from viral arthritis, tendon swelling, and mortality.

Sequential dendritic cell co-culture and IFNγ-based enrichment raise tumor-specific T cell yield and concentration for cancer immunotherapy.

Fetal porcine lung alveolar macrophage cells enable multi-passage ASF virus replication, supporting vaccine development and diagnostic research.

Novel CLuTV detection and vaccine tools help explain unexplained lumpsucker deaths and reduce mortality in aquaculture.

A CMV vector lacking UL128, UL130, UL146, and UL147 drives MHC-E-restricted CD8+ T cells to overcome HBV immunotolerance.

A derived MA104 cell line enables stable ASFV propagation while preserving protective efficacy through naturally attenuated virus production.

Peptide mixtures stimulate PBMCs to rapidly expand broad-spectrum CTLs for multiple viral antigens without infectious virus or dendritic cells.

Targeting a conserved SARS-CoV-2 spike RBD, mAb-52 blocks ACE2 binding to neutralize escape variants and reduce viral load.

Engineered CHO cells expressing CP77, K1L, and SPI-1 enable stable high-titer MVA replication without primary CEF contamination limits.

Combining aluminum adjuvant with motif-defined CpG oligodeoxynucleotides boosts HBV antibody response while adding Th1 immunity.

Nanoparticle display of L1, A33, and B5 antigens improves scalable poxvirus vaccine manufacturing while strengthening neutralizing protection.

A VZV gE vaccine paired with a TLR9 CpG adjuvant maintains immune response while reducing reactogenicity and severe adverse events.

Glycosylated HIV trimers on self-assembling ferritin nanoparticles use MBL and complement transport to reach germinal centers and boost antibody responses.

Engineered HIV immunogens expose conserved epitopes and stabilize trimers to prime precursor B cells and guide broadly neutralizing antibody maturation.

Monoclonal antibodies targeting conserved hMPV F protein epitopes neutralize genotypes A and B and help inhibit lung infection.

An inactivated reovirus vaccine with a polymer-lipid adjuvant enables safe early chick vaccination and protective immunity within days 1-14.

Multiple sub-effective intramuscular DNA vaccine doses given at different sites speed salmon immunity while reducing viral load and tissue damage.

Optimized V2 loop and CD4-binding HIV envelopes improve cross-reactive neutralizing antibody induction for broader HIV-1 vaccine response.

Targeting IL-4R signaling offers severe asthma and ABPA control while avoiding the systemic toxicities linked to high-dose corticosteroids.

Novel HPV16 E2, E6, and E7 epitopes matched to common HLA alleles improve T-cell targeting and help overcome CTL dysfunction in HNSCC.

Cationic lipids such as R-DOTAP boost type I interferon signaling and antigen cross-presentation to drive stronger cytotoxic T cell responses.

Non-infectious mock virus particles enable in-house viral clearance quantification, avoiding third-party infectivity assays and delays.

A 9-nucleotide RNA Booster sequence improves RNA stability and transgene expression, enabling transient vaccination with lower vector doses.

An adenovirus vaccine pairs a canine melanoma polyepitope with HSV-1 gD to overcome weak treatment options and trigger effector and memory T cells.

Deleting UL23, gE, and gI from live PRV creates a pig vaccine that maintains protection while limiting latent infection and viral shedding.

Combining a therapeutic vaccine with PD-1 or CTLA-4 blockade helps overcome T-cell exhaustion and improve antitumor immune response.

Recombinant PCV2 ORF2 with adjuvants helps young pigs reduce lymphadenopathy, lymphoid depletion, and related PCV2 symptoms.

A single recombinant MDV vector co-expresses ILTV and IBDV antigens to avoid construct overgrowth and enable stable poultry vaccination.

Engineered antibodies neutralize multiple lyssaviruses even after symptom onset or delayed exposure, extending rabies treatment options.

Adult fish serum at low concentration replaces fetal bovine serum to improve fish cell proliferation and support oral vaccine production.

Engineered SIV trimers mimic the V2 apex epitope to trigger broadly neutralizing antibody precursors despite HIV Env variability.

Chemically synthesized chimeric poxviruses remove harmful viral genes to preserve smallpox protection while reducing side effects and contraindications.

Co-expressing multiple CMV antigens in MVA vectors boosts neutralizing antibodies, ADCC, and T cell responses for broader protection.

Chemically synthesized vaccinia DNA is assembled and purified to preserve protection while reducing side effects and contamination risks.

A gE subunit vaccine pairs MLA, QS-21, and CoPoP liposomes to improve VZV immunogenicity, safety, and production yield.

A 15-valent L1 VLP vaccine expands HPV type coverage while balancing antigen ratios, adjuvant adsorption, and stability to limit immune interference.

Targeted Env mutations and nanoparticle display guide broadly neutralizing antibody induction while avoiding complex HIV antibody coevolution.

Histidine and sugar excipients with freeze-drying help herpesvirus formulations retain infectivity during storage and manufacturing.

Modified vaccinia viruses use sialidase and immune-boosting gene changes to cut antibody response and strengthen anti-tumor T-cell activity.

A single recombinant Marek's disease virus vector stabilizes ILTV and IBDV antigen expression to deliver multivalent poultry protection.

Plasmid-loaded dendritic cells, cytokines, and gas-permeable culture vessels speed CTL expansion against multiple viruses or tumor antigens.

mRNA sequences encoding rotavirus epitopes enable parenteral vaccination with broader serotype coverage and less cold-chain dependence.

Precisely spaced antigens and T cell helper epitopes on nucleic acid nanostructures strengthen germinal center responses and bnAb priming.

Modified SD sequences and tag removal let Tac promoter vectors produce soluble HPV L1 at higher yield with lower cost and fewer safety risks.

Aziridine inactivation preserves PRV antigen immunogenicity, improving vaccine protection against cohabitation transmission in Salmonid fish.

Stabilized HIV Env trimers with targeted sequence changes improve biochemical stability while eliciting broad neutralizing antibodies against diverse strains.

A replication-defective HSV-2 vaccine uses gD/gB antigen expression and dominant-negative UL9 to improve safety without losing immune protection.

Lipid nanoparticle mRNA encoding gp160, p24, and Nef epitopes broadens HIV strain coverage while reducing off-target risks.

Cationic and neutral liposomes pair Poly I:C with QS-21 to address insufficient CD4+ responses and strengthen cellular immunity.

Segmenting replication functions via a helper virus enables single cycle replicating adenoviruses to amplify antigen production and treat cancer.

Triple gene deletion eliminates immunosuppression and prevents viral shedding while enabling serological differentiation from wild-type strains.

Virus-like particle binding agents neutralize parvovirus B19 infections by mimicking viral structures, addressing the lack of effective vaccines.

DNA motif vaccines encode specific amino acid and glycosylation sequences to produce broadly neutralizing antibodies against HIV-1.

Biodegradable particles induce Th1 immunity via phagocytosis, improving feed conversion and weight gain at lower antigen doses.